CLINICAL TRIALS PROFILE FOR RPT193
✉ Email this page to a colleague
Clinical Trials for RPT193
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04271514 ↗ | A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis | Completed | RAPT Therapeutics, Inc. | Phase 1 | This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4. |
| NCT05399368 ↗ | An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis | Recruiting | RAPT Therapeutics, Inc. | Phase 2 | Phase 2 study of RPT193 in adults with atopic dermatitis |
| NCT05935332 ↗ | Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma | Suspended | RAPT Therapeutics, Inc. | Phase 2 | Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA). |
| NCT06087978 ↗ | Study of RPT193 in Healthy Adult Male Subjects | Completed | RAPT Therapeutics, Inc. | Phase 1 | Phase 1, open-label, absorption, metabolism, excretion, and mass balance study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for RPT193
Condition Name
Clinical Trial Locations for RPT193
Trials by Country
Clinical Trial Progress for RPT193
Clinical Trial Phase
Clinical Trial Sponsors for RPT193
Sponsor Name
